TransCode Therapeutics, Inc. a communiqué ses résultats financiers pour l'ensemble de l'exercice terminé le 31 décembre 2025.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has ...
"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, ...
Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
NASA Goddard Space Flight Center's Dr. Jennifer Wiseman explains the Hubble Space Telescope's view of the Pillars of Creation ...
Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
03/03 TransCode Therapeutics, Inc. et Unleash Immuno Oncolytics, Inc. concluent un accord de licence exclusif mondial, intégralement réglé et sans redevance CI 03/03 TransCode Therapeutics Inc conclut ...
Building on advances in routing, cloud, and audio, Ross demonstrated how its unified technology stack continues to evolve ...
Grass Valley and its Alliance partners will be at the Grass Valley booth (C2408) in Central Hall at NAB Show 2026 April 19-22 ...
Softron Media Services, a leading developer of professional video and broadcast software solutions for macOS, today announced new product updates and previews that will be showcased at NAB Show 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results